Paul Decker

Dr. Paul Decker


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JHJerome Hadjadj
Jerome Hadjadj
YNYann Nguyen
Yann Nguyen
DMDalila Mouloudj
Dalila Mouloudj
RBRim Bourguiba
Rim Bourguiba
MHMael Heiblig
Mael Heiblig
JDJeremie Dion
Jeremie Dion
Objectives Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease associated with somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutations. We aimed to evaluate the efficacy and safety of targeted therapies. Methods Multicentre retrospective study including patients with genetically proven VEXAS syndrome who had received at least one targeted therapy. Complete response (CR) was defined by a clinical remission, C-reactive protein (CRP) ≤10 mg/L and a ≤10 mg/day of prednisone-equivalent therapy, and partial response (PR) was defined by a clinical remission and a 50% reduction in CRP levels and glucocorticoid dose. Results 110 patients (median age 71 (68–79) years) who received 194 targeted therapies were included: 78 (40%) received Janus kinase (JAK) inhibitors (JAKi), 51 (26%) interleukin (IL)-6 inhibitors, 33 (17%) IL-1 inhibitors, 20 (10%) tumour necrosis factor (TNFα) blockers and 12 (6%) other targeted therapies. At 3 months, the overall response (CR and PR) rate was 24% with JAKi, 32% with IL-6 inhibitors, 9% with anti-IL-1 and 0% with TNFα blockers or other targeted therapies. At 6 months, the overall response rate was 30% with JAKi and 26% with IL-6 inhibitors. Survival without treatment discontinuation was significantly longer with JAKi than with the other targeted therapies. Among patients who discontinued treatment, causes were primary failure, secondary failure, serious adverse event or death in 43%, 14%, 19% and 19%, respectively, with JAKi and 46%, 11%, 31% and 9%, respectively, with IL-6 inhibitors. Conclusions This study shows the benefit of JAKi and IL-6 inhibitors, whereas other therapies have lower efficacy. These results need to be confirmed in prospective trials.

1 March 2022 in Autoimmunity Reviews
Verified
Journal Article
Closed access
PDPaul Decker
Paul Decker
TMT. Moulinet
T. Moulinet
FPF. Pontille
F. Pontille
MCM. Cravat
M. Cravat
MBM. De Carvalho Bittencourt
M. De Carvalho Bittencourt
RJR. Jaussaud
R. Jaussaud

9 December 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
BVBenjamin de Valence
Benjamin de Valence
MDMarion Delaune
Marion Delaune
YNYann Nguyen
Yann Nguyen
VJVincent Jachiet
Vincent Jachiet
MHMael Heiblig
Mael Heiblig
FRFrançois Rodrigues
François Rodrigues
Introduction Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an acquired autoinflammatory monogenic disease with a poor prognosis whose determinants are not well understood. We aimed to describe serious infectious complications and their potential risk factors. Methods Retrospective multicentre study including patients with VEXAS syndrome from the French VEXAS Registry. Episodes of serious infections were described, and their risk factors were analysed using multivariable Cox proportional hazards models. Results Seventy-four patients with 133 serious infections were included. The most common sites of infection were lung (59%), skin (10%) and urinary tract (9%). Microbiological confirmation was obtained in 76%: 52% bacterial, 30% viral, 15% fungal and 3% mycobacterial. Among the pulmonary infections, the main pathogens were SARS-CoV-2 (28%), Legionella pneumophila (21%) and Pneumocystis jirovecii (19%). Sixteen per cent of severe infections occurred without any immunosuppressive treatment and with a daily glucocorticoid dose ≤10 mg. In multivariate analysis, age >75 years (HR (95% CI) 1.81 (1.02 to 3.24)), p.Met41Val mutation (2.29 (1.10 to 5.10)) and arthralgia (2.14 (1.18 to 3.52)) were associated with the risk of serious infections. JAK inhibitors were most associated with serious infections (3.84 (1.89 to 7.81)) compared with biologics and azacitidine. After a median follow-up of 4.4 (2.5–7.7) years, 27 (36%) patients died, including 15 (56%) due to serious infections. Conclusion VEXAS syndrome is associated with a high incidence of serious infections, especially in older patients carrying the p.Met41Val mutation and treated with JAK inhibitors. The high frequency of atypical infections, especially in patients without treatment, may indicate an intrinsic immunodeficiency.

6 August 2022 in Autoimmunity Reviews
Verified
Journal Article
Closed access
CMClothilde Moriana
Clothilde Moriana
TMThomas Moulinet
Thomas Moulinet
RJRoland Jaussaud
Roland Jaussaud
PDPaul Decker
Paul Decker

1 September 2021 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
PDPaul Decker
Paul Decker
TMThomas Moulinet
Thomas Moulinet
BLBenjamin Lopez
Benjamin Lopez
SDSylvain Dubucquoi
Sylvain Dubucquoi
BBBernard Bonnotte
Bernard Bonnotte
RJRoland Jaussaud
Roland Jaussaud

1 March 2022 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
PDPaul Decker
Paul Decker
VSVincent Sobanski
Vincent Sobanski
TMThomas Moulinet
Thomas Moulinet
DLDavid Launay
David Launay
EHEric Hachulla
Eric Hachulla
RJRoland Jaussaud
Roland Jaussaud